No Data
Open Source Securities: DLL3 is a star target with high expression in SCLC, and various domestic new drugs can be expected in the future.
DLL3 is highly expressed in 80% of SCLC patients, providing a better solution for targeted therapy. Currently, only one product targeting this point has been approved for market, resulting in a favorable competitive landscape.
Zelgen Biopharma Gets Nod to Trial Cancer Drug Combination
Zhejiang Jiankang Pharmaceutical (688266.SH): The clinical trial for the injection ZG005 combined with hydrochloride gilteritinib tablets has been approved.
Zejin Pharmaceutical (688266.SH) announced that the company recently received notification from the National Pharmaceutical Administration (hereinafter referred to as...
Zejing Pharmaceutical (688266.SH): The injection ZG005 combined with hydrochloride giptanib tablets has received the notice of approval for drug clinical trials.
On December 25, Gelonghui reported that Zegeng Pharmaceutical (688266.SH) announced that it recently received the "Approval Notice for Clinical Trials of Pharmaceuticals" issued by the National Medical Products Administration, approving the clinical trials of injectable ZG005 combined with hydrochloride gicaxetine tablets for advanced solid tumors and refractory relapsed lymphoma.
Minsheng Securities: The results of medical insurance negotiations are now available, key products successfully included in the medical insurance catalog.
With the support of policies such as health insurance, the level of new drug research and development in China is continuously improving, the industrial scale is constantly expanding, and the number of new drugs under development in the country has jumped to the second place globally, accelerating the transition to high-quality innovation.
Zejing Pharmaceutical (688266.SH): Recombinant human thrombin included in the National Medical Insurance Pharmaceutical Directory for 2024.
On November 28th, Ge Longhui reported that Zejing Pharmaceutical (688266.SH) announced that the National Healthcare Security Administration, Ministry of Human Resources and Social Security released the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2024)" (referred to as the "National Medical Insurance Drug List"), Suzhou Zejing Biopharmaceutical Co., Ltd.'s independently developed recombinant human coagulation factor has been included in the National Medical Insurance Drug List through national medical insurance negotiations. The 2024 National Medical Insurance Drug List will take effect on January 1, 2025.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Popularity With Investors Under Threat As Stock Sinks 29%
